Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Leases (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Current Leases for 13 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 3.56% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 3.56% increase, with the full-year FY2025 number at $1.0 million, up 3.56% from a year prior.
  • Current Leases was $1.0 million for Q4 2025 at Madrigal Pharmaceuticals, down from $1.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.1 million in Q3 2025 to a low of $320000.0 in Q1 2021.
  • A 5-year average of $671150.0 and a median of $579500.0 in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: surged 118.11% in 2022, then tumbled 53.24% in 2023.
  • Madrigal Pharmaceuticals' Current Leases stood at $410000.0 in 2021, then skyrocketed by 46.83% to $602000.0 in 2022, then dropped by 12.46% to $527000.0 in 2023, then skyrocketed by 86.53% to $983000.0 in 2024, then rose by 3.56% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Current Leases are $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.0 million (Q2 2025).